Parkinson's Disease Investment Landscape

Investment Landscape: Parkinson's Disease

Overview

Investment Landscape: Parkinson's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Parkinson's Disease research.

Last updated: 2026-03-22 03:00 PT

Clinical Trial Pipeline

Total Clinical Trials: 4613 Active Trials (Recruiting/Active): 1061

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 337 |
| PHASE1, PHASE2 | 108 |
| PHASE2 | 485 |
| PHASE2, PHASE3 | 54 |
| PHASE3 | 253 |
| PHASE4 | 184 |
| NA | 2006 |
| Not Applicable | 1128 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 684 |
| ACTIVE_NOT_RECRUITING | 148 |
| NOT_YET_RECRUITING | 229 |
| COMPLETED | 2369 |
| TERMINATED | 250 |
| WITHDRAWN | 106 |

Top Therapeutic Approaches

• mitochondrial: 433 trials
• genetic: 209 trials
• neurotransmitter: 164 trials
• amyloid: 160 trials
• alpha-synuclein: 81 trials
• metal: 28 trials
• neuroinflammation: 26 trials
• metabolic: 26 trials

Investment Context

Parkinson's disease has 4,613 total clinical trials with 1,061 currently active. The Phase 3 portfolio (253 trials) is substantially smaller than Phase 2 (485), indicating a bottleneck in late-stage clinical development. This gap represents a critical investment opportunity.

Key Investment Themes

...

Investment Landscape: Parkinson's Disease

Overview

Investment Landscape: Parkinson's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Parkinson's Disease research.

Last updated: 2026-03-22 03:00 PT

Clinical Trial Pipeline

Total Clinical Trials: 4613 Active Trials (Recruiting/Active): 1061

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 337 |
| PHASE1, PHASE2 | 108 |
| PHASE2 | 485 |
| PHASE2, PHASE3 | 54 |
| PHASE3 | 253 |
| PHASE4 | 184 |
| NA | 2006 |
| Not Applicable | 1128 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 684 |
| ACTIVE_NOT_RECRUITING | 148 |
| NOT_YET_RECRUITING | 229 |
| COMPLETED | 2369 |
| TERMINATED | 250 |
| WITHDRAWN | 106 |

Top Therapeutic Approaches

• mitochondrial: 433 trials
• genetic: 209 trials
• neurotransmitter: 164 trials
• amyloid: 160 trials
• alpha-synuclein: 81 trials
• metal: 28 trials
• neuroinflammation: 26 trials
• metabolic: 26 trials

Investment Context

Parkinson's disease has 4,613 total clinical trials with 1,061 currently active. The Phase 3 portfolio (253 trials) is substantially smaller than Phase 2 (485), indicating a bottleneck in late-stage clinical development. This gap represents a critical investment opportunity.

Key Investment Themes

• Alpha-Synuclein Targeting: Major focus on oligomerization and aggregation inhibitors
• Neuroprotection: Strong pipeline for disease-modifying therapies
• Levodopa Optimization: Continued investment in motor symptom management
• Non-Motor Symptoms: Growing attention to cognitive, autonomic, and sleep manifestations

Emerging Investment Areas

The high number of terminated trials (250) highlights the need for novel approaches. LRRK2 inhibitors remain a major focus given the genetic link to sporadic PD. GBA-targeted therapies are emerging for the significant subset of patients with GBA mutations. Inflammatory modulation targeting NLRP3 and other inflammasome components represents a promising new frontier.

Priority Research Gaps

Late-Stage Development Bottleneck

Only 5.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.

Recommended Priorities

Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints

Trial Design Innovation: Adaptive trials and platform protocols

Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure

Therapeutic Target Priorities

Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:

• mitochondrial: 433 trials - Well-established
• genetic: 209 trials - Well-established
• neurotransmitter: 164 trials - Well-established
• amyloid: 160 trials - Well-established
• alpha-synuclein: 81 trials - Well-established

Investment Outlook

Near-Term Opportunities (1-3 Years)

Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.

Medium-Term Opportunities (3-5 Years)

Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.

Long-Term Vision (5-10 Years)

Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein-pathology)
• [LRRK2](/entities/lrrk2)
• [Clinical Trials: Parkinson's](/clinical-trials/parkinsons-disease)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, ClinicalTrials.gov (n.d.)